Striefler Jana K, Binder Phung T, Brandes Franziska, Rau Daniel, Wittenberg Silvan, Kaul David, Roohani Siyer, Jarosch Armin, Schäfer Frederik M, Öllinger Robert, Märdian Sven, Bullinger Lars, Eckardt Kai-Uwe, Kruse Jan, Flörcken Anne
Department of Internal Medicine II, Oncology/Hematology/BMT/Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Cancer Manag Res. 2023 Mar 27;15:321-334. doi: 10.2147/CMAR.S400430. eCollection 2023.
Prognosis of sarcoma patients is improving, with a better understanding of sarcomagenesis revealing novel therapeutic targets. However, aggressive chemotherapy remains an essential part of treatment, bearing the risk of severe side effects that require intensive medical treatment. Available data on the characteristics and clinical outcome of sarcoma patients admitted to intensive care units (ICU) are sparse.
We performed a retrospective analysis of sarcoma patients admitted to the ICU from 2005 to 2022. Patients ≥18 years with histologically proven sarcoma were included in our study.
Sixty-six patients were eligible for analysis. The following characteristics had significant impact on overall survival: sex (p=0.046), tumour localization (p=0.02), therapeutic intention (p=0.02), line of chemotherapy (p<0.001), SAPS II score (p=0.03) and SOFA score (p=0.02).
Our study confirms the predictive relevance of established sepsis and performance scores in sarcoma patients. For overall survival, common clinical characteristics are also of significant value. Further investigation is needed to optimize ICU treatment of sarcoma patients.
随着对肉瘤发生机制的深入了解揭示了新的治疗靶点，肉瘤患者的预后正在改善。然而，积极的化疗仍然是治疗的重要组成部分，存在严重副作用的风险，需要强化医疗治疗。关于入住重症监护病房（ICU）的肉瘤患者的特征和临床结局的现有数据很少。
我们对2005年至2022年入住ICU的肉瘤患者进行了回顾性分析。纳入研究的患者年龄≥18岁，组织学确诊为肉瘤。
66例患者符合分析条件。以下特征对总生存期有显著影响：性别（p=0.046）、肿瘤部位（p=0.02）、治疗意图（p=0.02）、化疗线数（p<0.001）、简化急性生理学评分II（SAPS II）（p=0.03）和序贯器官衰竭评估（SOFA）评分（p=0.02）。
我们的研究证实了既定的脓毒症和性能评分在肉瘤患者中的预测相关性。对于总生存期而言，常见的临床特征也具有重要价值。需要进一步研究以优化肉瘤患者的ICU治疗。
